Pharmacogenomics of metabolic effects of rosiglitazone

Pharmacogenomics

Volumn 9, Issue 2, 2008, Pages 141-155

  Šeda, Ondrej ^a,b,c   Šedová, Lucie ^a,b   Oliyarnyk, Olena ^c   Kazdova, Ludmila ^c   Křenova, Drahomíra ^b   Corbeil, Gilles ^a   Hamet, Pavel ^a   Tremblay, Johanne ^a   Křen, Vladimir ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Animal models; Insulin resistance; Insulin sensitizer; Microarray; Oxidative stress; Rosiglitazone

Indexed keywords

ADAM PROTEIN; ADAM PROTEIN 7; AQUAPORIN 9; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE 1B; CATECHOL METHYLTRANSFERASE; CAVEOLIN 1; GLUCOSE; LEPTIN; PROSTAGLANDIN D2; ROSIGLITAZONE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; FATTY ACID; GLYCOGEN; LIPID; RNA; SUCROSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE OXIDATION; GLUCOSE TOLERANCE; GLYCOGEN SYNTHESIS; HIGH FIBER DIET; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID PEROXIDATION; LIPID STORAGE; LIPOGENESIS; MALE; METABOLIC SYNDROME X; MORPHOMETRICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; RAT; RAT STRAIN; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ANIMAL; BIOSYNTHESIS; BROWN NORWAY RAT; CARBOHYDRATE DIET; CHOLESTEROL INTAKE; DIET; DRUG EFFECT; GENETICS; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; ISOLATION AND PURIFICATION; LIVER; METABOLISM; MICROARRAY ANALYSIS; OXIDATION REDUCTION REACTION;

ANIMALIA; RATTUS;

ADIPOSE TISSUE; ADIPOSE TISSUE, WHITE; ANIMALS; CHOLESTEROL, DIETARY; DIET; DIETARY CARBOHYDRATES; FATTY ACIDS; GENE EXPRESSION; GLUCOSE; GLUCOSE TOLERANCE TEST; GLYCOGEN; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; LIVER; METABOLIC SYNDROME X; MICROARRAY ANALYSIS; OXIDATION-REDUCTION; OXIDATIVE STRESS; RATS; RATS, INBRED BN; RATS, INBRED STRAINS; RNA; SUCROSE; THIAZOLIDINEDIONES;

EID: 42449100763     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.2.141     Document Type: Article

References (71)

1. Yach D, Stuckler D, Brownell KD: Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat. Med. 12, 62-66 (2006).
2. Seda O, Tremblay J, Sedova L, Hamet P: Integrating genomics and transcriptomics with geo-ethnicity and the environment for the resolution of complex cardiovascular diseases. Curr. Opin. Mol. Ther. 7, 583-587 (2005).
3. Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, Mahley RW: Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J. 7, 10-28 (2007).
4. Olefsky JM: Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists. J. Clin. Invest. 106, 467-472 (2000).
5. Yki-Jarvinen H: Thiazolidinediones. N. Engl. J. Med. 351, 1106-1118 (2004).
6. Cantello BC, Cawthorne MA, Cottarn GP et al.: O-(heterocyclylamino) alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem. 37, 3977-3985 (1994).
7. Seda O, Kazdova L, Krenova D, Kren V: Rosiglitazone improves insulin resistance, lipid profile and promotes adiposity in a genetic model of metabolic syndrome X. Folia Biol. 48, 237-241 (2002).
8. Gerstein HC, Yusuf S, Bosch J et al.: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368, 1096-1105 (2006).
9. Kahn SE, Haffner SM, Heise MA et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355, 2427-2443 (2006).
10. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356(24), 2457-2471 (2007).
11. Nabel EG, Shurin SB, Simons-Morton DG, Gordon D: Data and safety monitoring of rosiglitazone trials. Lancet 369, 2077 (2007).
12. Singh S, Loke YK, Furberg CD: Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 30(8), 2148-2153 (2007).
13. Home PD, Jones NP, Pocock SJ et al.: Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet. Med. 24, 626-634 (2007).
14. Berlie HD, Kalus JS, Jaber LA: Thiazolidinediones and the risk of edema: a meta-anaiysis. Diabetes Res. Clin. Pract. 76, 279-289 (2007).
15. Adams M, Montague CT, Prins JB et al.: Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. J. Clin. Invest. 100, 3149-3153 (1997).
16. Home PD, Pocock SJ, Beck-Nielsen H et al.: Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N. Engl. J. Med. 357(1), 28-38 (2007).
17. Scheen AJ: Thiazolidinediones and liver toxicity. Diabetes Metab. 27, 305-313 (2001).
18. Marcy TR, Britton ML, Blevins SM: Second-generation thiazolidinediones and hepatotoxicity. Ann. Pharmacother. 38, 1419-1423 (2004).
19. Grey A, Bolland M, Gamble G et a.: The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 92, 1305-1310 (2007).
20. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B: Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148, 2669-2680 (2007).
21. Colucciello, M: Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch. Ophthalmol. 123, 1273-1275 (2005).
22. Seda O, Sedova L: Peroxisome proliferator-activated receptors as molecular targets in relation to obesity and Type 2 diabetes. Pharmacogenomics 8, 587-596 (2007).
23. Seda O, Kazdova L, Krenova D, Kren V: Rosiglitazone falls to improve hypertriglyceridemia and glucose tolerance in CD36-deficient BN.SHR4 congenic rat strain. Physol. Genomics 12, 73-78 (2003).
24. Proietto J, Filippis A, Nakhla C, Clark S: Nutrient-induced insulin resistance. Mol. Cell. Endocrinol. 151, 143-149 (1999).
25. Seda O, Sedova L, Kazdova L, Krenova D, Kren V: Metabolic characterization of insulin resistance syndrome feature loci in three brown Norway-derived congenic strains. Folia Biol. 48, 81-88 (2002).
26. Seda O, Liska F, Krenova D et al.: Differential linkage of triglyceride and glucose levels on rat chromosome 4 in two segregating rat populations. Folia biologica 49, 223-226 (2003).
27. Sedova L, Kazdova L, Seda O, Krenova D, Kren V: Rat inbred PD/cub strain as a model of dyslipidemia and insulin resistance. Folia Biol. 46, 99-106 (2000).
28. Kren V, Krenova D, Bila V, Zdobinska M, Zidek V, Pravenec M: Recombinant inbred and congenir strains for mapping of genes that are responsible for spontaneous hypertension and other risk factors of cardiovascular disease. Folia Biol. 42, 155-158 (1996).
29. Domas P, Sun Y, Corbell G et al.: Mapping of quantitative trait loci (QTL) of differential stress gene expression in rat recombinant inbred strains. J. Hypertens. 18, 545-551 (2000).
30. Sedova L, Seda O, Krenova D, Kren V, Kazdova L: Isotretinoin and fenofibrate induce adiposity with distinct effect on metabolic profile in a rat model of the insulin resistance syndrome. Int. J. Obes. Relat. Metab. Disord. 28, 719-725 (2004).
31. Sedova L, Seda o, Kazdova L et al.: Sucrose feeding during pregnancy and lactation elicits distinct metabolic response in offspring of an inbred genetic model of metabolic syndrome. Am. J. Physiol. Endocrinol. Metab. 292(5), E1318-E1324 (2007).
32. Seda O, Liska F, Krenova D et al.: Dynamic genetic architecture of metabolic syndrome attributes in the rat. Physiol. Genomics 21, 243-252 (2005).
33. Katz A, Nambi SS, Mather K et al.: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab. 85, 2402-2410 (2000).
34. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419 (1985).
35. Vrana A, Kazdova L: Insulin sensitivity of rat adipose tissue and of diaphragm in vitro: effect of the type of dietary carbohydrate (starch-sucrose). Life Sci. II9, 257-265 (1970).
36. Vrana A, Poledne R, Fabry P, Kazdova L: Palmitate and glucose oxidation by diaphragm of rats with fructose-induced hypertriglyceridemia. Metab. Clin. Exp. 27, 885-888 (1978).
37. Skottova N, Kazdova L, Oliyarnyk O Vecera R, Sobolova L, Ulrichova J: Phenolics-rich extracts from Silybum marianum and Prunella vulgaris reduce a high-sucrose diet induced oxidative stress in hereditary hypertriglyceridemic rats. Pharmacol. Res. 50, 123-130 (2004).
38. Vecera R, Orolin J, Skottova N et al.: The influence of maca ( Lepidium meyenii) on antioxidant status, lipid and glucose metabolism in rat. Plant Foods Hum. Nutr. 62(2), 59-63 (2007).
39. Naito C, Kawamura M, Yamamoto Y: Lipid peroxides as the initiating factor of atherosclerosis. Ann. NY Acad. Sci. 676, 27-45 (1993).
40. Pfaff MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, E45 (2001).
41. Wolford JK, Yeatts KA, Dhanjal SK et al.: Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes 54, 3319-3325 (2005).
42. Roses AD: Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet. 5, 645-656 (2004).
43. Tonjes A, Scholz M, Loeffler M, Stumvoll M: Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ with pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 29, 2489-2497 (2006).
44. Kirchheiner J, Thomas S, Bauer S et al.: Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin. Pharmacol. Ther. 80, 657-667 (2006).
45. Kang ES, Park SY, Kim HJ et al.: The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with Type 2 diabetes. Diabetes Care 28, 1139-1144 (2005).
46. Wang G, Wang X, Zhang Q, Ma Z: Response to proglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with Type 2 diabetes mellitus. Int. J. Clin. Pract. 61, 552-557 (2007).
47. Kang ES, Cha BS, Kim HJ et al.: The 11482G>A polymorphism in the perilipin gene is associated with weight gain with rosiglitazone treatment in Type 2 diabetes. Diabetes Care 29, 1320-1324 (2006).
48. Qi N, Kazdova L, Zidek V et al.: Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone. J Biol. Chem. 277, 48501-48507 (2002).
49. Pan HJ, Reifsnyder P, Vance DE, Xiao Q, Leiter EH: Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of Type 2 diabetes. Diabetes 54, 1854-1862 (2005).
50. Leiter EH, Reifsnyder PC, Zhang W, Pan HJ, Xiao Q, Mistry J: Differential endocrine responses to rosiglitazone therapy in new mouse models of Type 2 diabetes. Endocrinology 147, 919-926 (2006).
51. Svenson KL, Von Smith R, Magnani PA et al.: Multiple trait measurements in 43 inbred mouse strains capture the phenotypic diversity characteristic of human populations. J. Appl. Physiol. 102, 2369-2378 (2007)
52. Belfort R, Harrison SA, Brown K et al.: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355, 2297-2307 (2006).
53. Quinkler M, Bujalska IJ, Tomlinson JW, Smith DM, Stewart PM: Depot-specific prostaglandin synthesis in human adipose tissue. a novel possible methanism of adipogenesis. Gene 380, 137-143 (2006).
54. Pico C, Puigserver P, Oliver P, Palou A: 2-methoxyestradiol, an endogenous metabolite of 17β-estradiol, inhibits adipocyte proliferation. Mol. Cell. Biochem. 189, 1-7 (1998).
55. Dimitriadis G, Leighton B, Parry-Billings M et al.: Effects of glucocorticoid excess on the sensitivity of glucose transport and metabolism to insulin in rat skeletal muscle. Biochem. J. 321 (Pt 3), 707-712 (1997).
56. Hwang J, Kleinhenz DJ, Lassegue B, Griendling KK, Dikalov S, Hart CM: Peroxisome proliferator-activated receptor-γ ligands regulate endothelial membrane superoxide production. Am. J. Physiol. Cell. Physiol. 288, C899-C905 (2005).
57. Girnun GD, Domann FE, Moore SA, Robbins ME: Identification of a functional peroxisome proliferator-activated receptor responce element in the rat catalase promoter Mol. Endocrinol. 16, 2793-2801 (2002).
58. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P: In Type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 27, 484-490 (2004).
59. O'Brien ML, Twaroski TP, Cunningham ML, Glauert HP, Spear BT: Effects of peroxisome proliferators on antioxidant enzymes and antioxidant vitamins in rats and hamsters. Toxicol. Sci. 60, 271-278 (2001).
60. Reynolds LR, Kingsley FJ, Karounos DG, Tannock LR: Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in Type 2 diabetes. Diabetes Res. Clin. Pract. 77, 180-187 (2007).
61. Kallen CB, Lazar MA: Antidiabetic thiazolidinediones inhibit leptin ( ob) gene expression in 3T3-L1 adipocytes. Proc. Natl Acad. Sci. USA 93, 5793-5796 (1996).
62. Wilson-Fritch L, Nicoloro S, Chouinard M et al.: Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J. Clin. Invest. 114, 1281-1289 (2004).
63. Rojek AM, Skowronski MT, Fuchtbauer EM et al.: Defective glycerol metabolism in aquaporin 9 (AQP6) knockout mice. Proc. Natl Acad. Sci. USA 104, 3609-3614 (2007).
64. Oh J, Woo JM, Choi E et al.: Molecular, biochemical, and cellular characterization of epididymal ADAMs, ADAM7 and ADAM28. Biochem. Biophys. Res. Comm. 331, 1374-1383 (2005).
65. Moraes RC, Blondet A, Birkenkamp-Demtroeder K et al.: Study of the alteration of gene expression in adipose tissue of diet-induced obese mice by microarray and reverse transcription-polymerase chain reaction analyses. Endocrinology 144, 4773-4782 (2003).
66. Pan HJ, Lin Y, Chen YE, Vance DE, Leiter EH: Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of Type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism. Vasc. Pharmacol. 45, 65-71 (2006).
67. Watkins SM, Reifsnyder PR, Pan HJ, German JB, Leiter EH: Lipid metabolome, wide effects of the PPARγ agonist rosiglitazone. J. Lipid Res. 43, 1809-1817 (2002).
68. Hubner N, Wallace CA, Zimdahl H et al.: Integrated transcriptional profiling and linkage analysis for identification of genes underlying disease. Nat Genet. 37, 243-253 (2005).
69. Glazier AM, Nadeau JH, Aitman TJ: Finding genes that underlie complex traits. Science 298, 2345-2349 (2002).
70. Loscalzo J, Kohane I, Barabasi AL: Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol. Syst. Biol. 3, 124 (2007).
71. Seda O: Comparative gene map of hypertriglyceridaemia. Folia Biol. 50, 43-57 (2004).